DR. CHETAN BETTEGOWDA, MD,PHD
Medical Practice at Wolfe St, Baltimore, MD
License number
Maryland P19991
Category
Medical Practice
Type
Neurological Surgery
License number
Maryland D74560
Category
Medical Practice
Type
Neurological Surgery
Address
Address
600 N Wolfe St, Baltimore, MD 21287
Phone
(443) 847-7168
(410) 955-6406
(410) 955-6406
Personal information
See more information about CHETAN BETTEGOWDA at radaris.comName
Address
Phone
2201 Rogene Dr, Baltimore, MD 21209
5239 Morning Dove Way, Perry Hall, MD 21128
Baltimore, MD
127 Versailles Cir, Towson, MD 21204
2201 Rogene Dr, Baltimore, MD 21209
Organization information
See more information about CHETAN BETTEGOWDA at bizstanding.comChetan Bettegowda MD
600 N Wolfe St, Baltimore, MD 21287
Categories:
General Surgeons, Neurology Physicians & Surgeons
Phone:
(410) 955-5000 (Phone)
Professional information
Dr. Chetan Bettegowda, Baltimore MD - MD (Doctor of Medicine)
Specialties:
Neurosurgery
Address:
JOHNS HOPKINS DEPARTMENT OF NEUROSURGERY
600 N Wolfe St, Baltimore 21287
(410) 955-2264 (Phone)
600 N Wolfe St, Baltimore 21287
(410) 955-2264 (Phone)
Languages:
English
Education:
Medical School
Johns Hopkins University / School of Medicine
Graduated: 2002
Johns Hopkins University / School of Medicine
Graduated: 2002
Chetan Bettegowda, Baltimore MD
Specialties:
Neurological Surgery
Work:
Johns Hopkins Outpatient Center
601 N Caroline St, Baltimore, MD 21287
601 N Caroline St, Baltimore, MD 21287
Education:
Johns Hopkins University (2005)
Chetan Bettegowda, Baltimore MD
Specialties:
Neurosurgeon
Address:
600 N Wolfe St, Baltimore, MD 21287
Combination Bacteriolytic Therapy For The Treatment Of Tumors
US Patent:
2007014, Jun 28, 2007
Filed:
Oct 21, 2004
Appl. No.:
10/568765
Inventors:
Long Dang - Baltimore MD, US
Chetan Bettegowda - Baltimore MD, US
Kenneth Kenzler - Bel Air MD, US
Bert Vogelstein - Baltimore MD, US
Chetan Bettegowda - Baltimore MD, US
Kenneth Kenzler - Bel Air MD, US
Bert Vogelstein - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 35/74, A61K 31/337, A61K 31/427
US Classification:
424093400, 424623000, 514449000, 514365000
Abstract:
Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sponzlated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate. A single intravenous injection of spores plus selected microtubule-interacting agents was able to cause regressions of several tumors in the absence of excessive toxicity.
Combination Bacteriolytic Therapy For The Treatment Of Tumors
US Patent:
8613917, Dec 24, 2013
Filed:
Aug 5, 2011
Appl. No.:
13/198850
Inventors:
Long Dang - Baltimore MD, US
Chetan Bettegowda - Towson MD, US
Kenneth W. Kinzler - Bel Air MD, US
Bert Vogelstein - Baltimore MD, US
Chetan Bettegowda - Towson MD, US
Kenneth W. Kinzler - Bel Air MD, US
Bert Vogelstein - Baltimore MD, US
Assignee:
The Johns Hopkins University - Baltimore MD
International Classification:
A61K 35/00, A01N 63/00, A01N 63/02, C12N 1/20, C12N 3/00
US Classification:
424 9341, 424780, 435242, 4352527, 435842
Abstract:
Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria. Mechanistic studies showed that the microtubule destabilizers, but not the microtubule stabilizers, radically reduced blood flow to tumors, thereby enlarging the hypoxic niche in which spores could germinate.